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Familial Alzheimer’s disease (AD [MIM 104300]) has been a focus of intense investigation,
primarily in Caucasian families from Europe and North America families. Although the late-
onset form of familial AD, beginning after age 65 years, has been linked to regions on
chromosomes 10q and 12p, the specific genetic variants have not yet been consistently
identified. Using a unique cohort of families of Caribbean Hispanics ancestry, we screened the
genome using 340 markers on 490 family members from 96 families with predominantly late-
onset AD. We observed the strongest support for linkage on 18q (LOD¼ 3.14). However, 17
additional markers (chromosomes 1–6, 8, 10, 12, and 14) exceeded a two-point LOD score of
1.0 under the affecteds-only autosomal dominant model or affected sibpair model. As we
previously reported the fine-mapping effort on 12p showing modest evidence of linkage, we
focused our fine-mapping efforts on two other candidate regions in the current report, namely
10q and 18q. We added 31 family members and eight additional Caribbean Hispanic families to
fine map 10q and 18q. With additional microsatellite markers, the evidence for linkage for 18q
strengthened near 112 cM, where the two-point LOD score for D18S541 was 3.37 and the
highest NPL score in that region was 3.65 (P¼ 0.000177). This narrow region contains a small
number of genes expressed in the brain. However, at 10q (134–138 cM), the NPL score
decreased from 3.15 (P¼ 0.000486) to 2.1 (P¼ 0.0218), but two broad peaks remained
overlapping with previously reported peaks. Our results provide modest support for linkage
on 10q and 12p in this cohort of Caribbean Hispanic families with familial Alzheimer’s disease,
and strong evidence for a new locus on 18q.
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The e4 variant of APOE (APOE [MIM 107741]) is the
only known gene associated with increased risk of
late-onset Alzheimer’s disease (AD),1 but this variant
explains only 20% of the attributable risk.2 Genetic
linkage studies suggest additional putative loci for
late-onset AD.3–8 A locus on chromosome 12p11 (AD5
[MIM 602096]) that confers modest susceptibility to
AD was found several years ago,5,9,10 and a locus on
chromosome 10q24 (AD6 [MIM 605526]) segregating
with either the diagnosis of AD6,8 or with elevated
plasma amyloid b has also been identified.7 In
families where AD has been confirmed by postmor-
tem examination, Pericak-Vance and associates4 also
reported a susceptibility locus on chromosome 9p22.
All of these studies have been conducted in Cauca-
sian families from North America or Europe.
The frequency of AD in Caribbean Hispanics was
observed to be two- to three-fold higher compared
with non-Hispanics living in a New York commu-
nity,11 but the association between APOE-e4 and
sporadic AD in a population-based study including
Received 29 April 2004; revised 29 April 2004; accepted 06 May
2004
Correspondence: R Mayeux, MD, MSc, Gertrude H. Sergievsky
Center, 630 West 168th Street, Columbia University, NY 10032,
New York, USA. E-mail: rpm2@columbia.edu
* These authors contributed equally to the work involved in this
investigation.
Molecular Psychiatry (2004) 9, 1042–1051
& 2004 Nature Publishing Group All rights reserved 1359-4184/03 $30.00
www.nature.com/mp
Caribbean Hispanics was weak.12,13 To investigate the
genetics of AD in this population, we initiated a
linkage study. Our initial results included a strong
association between APOE-e4 and late-onset familial
AD,14 a founder mutation in presenilin 1 (PSEN1
[MIM 104311]) among families with early-onset AD,15
and modest evidence for linkage to chromosome 12p
for late-onset AD in this population.16 In this report,
we describe the results of fine mapping on chromo-
somes 10q and 18q based on the results of the first




We initially studied 490 individuals (394 relatives and
96 probands) of 96 Caribbean Hispanic families. In the
second-stage fine mapping, we added eight families for
a total of 521 individuals (417 relatives and 104
probands) of 104 families. The sampling design and
detailed characteristics of the participants have been
described elsewhere.14 Briefly, multiple sources were
used to recruit families. We recruited from clinics in
the Dominican Republic and Puerto Rico, as well as
the Alzheimer’s Disease Research Center Memory
Disorders Clinic at Columbia University in the New
York City. To augment family recruitment, we adver-
tized in local newspapers and media in Dominican
Republic, Puerto Rico, and New York. In addition, we
recruited probands identified in an epidemiological
study in northern Manhattan11 when the informant
reported family members with dementia.
All patients and participating family members were
examined and blood was obtained. Patients with AD
met the National Institute of Neurological and Com-
municative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association (NINCDS-
ADRDA).17 The Clinical Dementia Rating Scale (CDR)
was used to rate disease severity.18 Brain imaging and
other laboratory studies were reviewed when avail-
able, and offered when medically required for
diagnosis. The battery of neuropsychological tests
used had been developed and evaluated extensively
in Hispanics.19–21 Age at onset was based on the age at
which the memory complaint was first reported, or if
unavailable the age at first examination. Patients from
four families with AD had autopsies confirming the
clinical diagnoses of AD. In the current genome scan,
we conducted linkage analysis using possible AD as
affected. The affection status for family members with
other forms of dementia or mild cognitive impairment
was classified as unknown or ambiguous for the
linkage analyses.
The Institutional Review Board of Columbia Pres-
byterian Medical Center and Columbia University
Health Sciences and the Bioethics National Commit-
tee for Research in the Dominican Republic approved
the study. Informed consent was obtained either from
the participant or from a family member (surrogate)
when the individual was demented.
Genotyping
First-stage mapping Using the first set of 96 families,
we genotyped 340 autosomal microsatellite markers
with an average inter-marker distance of 10.2 cM.
Genotypes were generated as described in our earlier
report.16 APOE genotypes were performed using a
standard method22 with slight modification.12
Genotype data were stored in LABMAN,23 and then
output in standard LINKAGE file format for analysis.
Maps from the Marshfield Medical Research
Foundation24 and the Genome Database were used
for locus order and inter-marker distance. Order was
confirmed by comparison with the Human Genome
Browser.25 Two or three individuals from CEPH pedig-
rees were included on each PCR plate. Discrepant
genotypes were observed in 176 of 8607 genotypes for
an error rate of 2.04%. This is a maximum error rate as
no families were spread over more than one PCR
plate, reducing plate-to-plate variation. Errors that
caused mendalization errors in a family with greater
than two samples were corrected. Data were comple-
ted for 96.1% of the sample–marker combinations.
Second-stage mapping Following the first-stage
mapping, we observed that 18q, 10q, and 12p showed
the strongest support for linkage either in two-point
or multipoint analyses. We previously reported our
results on the fine-mapping analysis for 12p.16 Thus,
we focused our fine-mapping efforts on 18q and 10q
using 104 families (96 families from the first-stage
mapping plus eight new families). For 18q, we
genotyped 18 additional markers from 96 to 126 cM,
with an average inter-marker distance in the second-
stage mapping of 1.8 cM. For 10q, we genotyped 12
additional markers between 90 and 160 cM, where our
peaks were observed, resulting in an average inter-
marker distance of 3.0 cM. We also genotyped eight
additional markers between 42 and 94 cM, where
other researchers found peaks, resulting in an average
inter-marker distance of 4.1 cM. Following this, we
then genotyped additional markers near D10S677
(117.4 cM) and D10S1230 (142.8 cM), where we had
previously observed suggestive peaks.
Prior to the genome scan, we used 100 markers to
examine for relationships among family members
using the programs PEDCHECK26 and RELATIVE.27
As RELATIVE uses allele sharing among siblings (as
well as non-sibling relatives) to test for nonpaternity,
it is well suited for late-onset diseases like AD. Based
on the results, we corrected the relationships (eg, full
sibling to half-sibling), and we excluded individuals
who were determined to be biologically unrelated.
Statistical analysis
In the first-stage scan, we performed a two-point
affecteds-only analysis and multipoint affected rela-
tive pair analysis. For two-point linkage analysis, we
carried out an affecteds-only analysis assuming
autosomal dominant inheritance and also an affected
sibpair analysis using ANALYZE.28 For multipoint
Alzheimer’s disease genome scan in Caribbean Hispanics
JH Lee et al
1043
Molecular Psychiatry
nonparametric linkage analysis, we used GENEHUN-
TER2.29 When necessary, uninformative nonfounders
were excluded (eg, unaffected children) to circum-
vent the computational limitation of the software. For
all linkage analyses, we assumed a susceptibility
allele frequency of 0.001. Allele frequencies for all
markers were based on data derived from all partici-
pating family members.23,30 This method gives asymp-
totically unbiased estimates of the allele frequencies,
thereby reducing the risk of false positives.31 As
linkage analysis is sensitive to allele frequency, we re-
analyzed the three candidate regions after re-comput-
ing allele frequency by randomly selecting one
individual from each family. None of the markers in
the three candidate regions showed significant differ-
ences in allele frequency by either method of
estimating allele frequency (data not shown).
In the second-stage mapping, we carried out a series
of linkage and family-based association analyses with
additional markers using 104 families. First, two-
point and multipoint linkage analyses were com-
pleted using the same models as in the first-stage
mapping. Second, a family-based association analysis
was implemented in Sib-TDT using the AD pheno-
type. Allelic association is expressed as a Z-score, and
P-values are computed based on the normal distribu-
tion approximation.32 Third, we conducted a joint
analysis of linkage and linkage disequilibrium, as
implemented in PSEUDOMARKER.33 This method
approximates a model-free affected relative pair
approach, improves the power by jointly analyzing
linkage and linkage disequilibrium, and does not
break pedigrees into separate relative pairs. For 10q
only, we tested allelic association for a series of
markers between D10S1239 and D10S1237 using
SNPs and age at onset as the phenotype implemented
in QTDT to confirm the findings by Li et al.34,35 Lastly,
because we16 and others3,9,36,37 have shown that there
may be gene–gene interaction with APOE, we con-
ducted two-point and multipoint linkage analyses,
conditional on the APOE e4 allele. For this purpose,
we considered an individual with AD and at least one
APOE e4 allele affected. An individual was consid-
ered unknown otherwise (e4-positive conditional
analysis). To determine the independent effect of
APOE, we conducted an analogous conditional
linkage analysis, in which an individual with AD
was considered affected in the absence of an APOE e4
allele (e4-negative conditional analysis). By carrying
out the conditional analysis, it is not necessary to
arbitrarily stratify families into APOE e4-positive or -
negative families. However, we did not test for family-
based allelic association because we treated unaf-
fected individuals as well as affected individuals
without a copy of e4 as unknown.
Results
Subjects and families
In the first-stage mapping, we studied 96 families
with at least two individuals with AD, which
included 490 family members. The demographic
and clinical characteristics of the participating family
members are presented in Table 1. In addition to
probands, approximately four relatives were exam-
ined per family, which included affected as well as
unaffected individuals. The mean age at onset for
affected individuals was 73.6 years. The majority of
the families (85.7%) were from the Dominican
Republic, 10.2% were from Puerto Rico, and 4.1%
came from elsewhere in the Caribbean. Previously, we
have shown that the study population is relatively
homogeneous.15
Overall, 237 individuals met the criteria for prob-
able AD, 157 were unaffected. The study included
families with affected sibpairs as well as families with
multiple individuals with AD who were distantly
related (eg, avunculars, cousins). There were 12
families with five or more affected family members
and 12 families with four affected members. Approxi-
mately one-half of the families included two affected
members. Eight families had predominantly early-
onset (defined as the majority of affected individuals
having onset before age 65 years) disease and 88
families had late-onset AD.
In the second-stage mapping, we added eight
families for a total of 104 families and 521 family
members. We found the clinical characteristics for the
additional families to be similar to those of the
families used in the first-stage mapping (Table 1).
The frequency of APOE-e4 among affected indivi-
duals was significantly higher than expected under
the null hypothesis of no association (Z¼ 4.26,
P¼1.01105, allele frequencies in Table 1). We
were unable to compare allele frequencies for highly
Table 1 Description of Caribbean Hispanic families
Characteristics First stage Second stage
Number of families 96 104
Number of relatives examined 394 417
Individuals per family 5.1 5.1
Proportion of women (%) 66.7% 66.8%
Mean age at onset of AD (years) 73.6 73.5
Affection status




Z5 affecteds 12 (82:54) 12 (82:55)
4 affecteds 12 (48:24) 13 (52:27)
3 affecteds 21 (63:38) 21 (63:42)
2 affecteds 51 (102:57) 58 (116:65)
Totala 96 (295:173) 104 (313:189)
APOE—e4 allele frequency
Probable AD 48.8% 47.0%
Unaffected 35.8% 35.4%
aIn all, 22 individuals were classified as unknown.
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polymorphic microsatellite markers between indivi-
duals from the Puerto Rico and Dominican Republic
because there were too few individuals from the
Puerto Rico to make such comparisons meaningful.
First-stage mapping
Two-point analysis The positive results of two-point
analyses for 340 autosomal microsatellite markers
with an average inter-marker distance of 10.2 cM
under the genetic homogeneity and affected sibpair
models are shown in Table 2 (see supplementary
graphs). We observed 17 markers exceeding an LOD
score of 1.0 using either model. The three highest two-
point LOD scores were 3.26 for D18S541 in the
affected sibpair model, 2.44 for D18S844 in the
homogeneity model, and 2.0 for D14S587 in the
affected sibpair model. When restricted to late-onset
families, the LOD score increased to 3.62 for D18S541
and to 2.98 for D18S844 under the homogeneity
model, but decreased to 1.69 for D14S587 under the
affected sibpair model.
Multipoint analysis Two of the highest multipoint
NPL scores were observed on 18q and 10q (see
supplementary material). On 18q, the strongest
support was observed for D18S541 (NPL¼ 2.70,
P¼ 0.0022; 112.3 cM), and the NPL scores for the
adjacent markers were 1.42 (P¼ 0.0646) for D18S1270
and 1.82 (P¼ 0.026; 96.5 cM) for D18S844 (119.7 cM).
The peak spanned over 20 cM. For 10q, the major
peak was at D10S1230 with an NPL score of 3.15
(P¼ 0.000487), and a minor peak was observed at
D10S677 with an NPL score of 1.54 (P¼ 0.048502;
117.4 cM). Although the major peak spans
approximately 35 cM, the two peaks combined span
as much as 60 cM.
Second-stage mapping
18q We re-examined the entire region between
D18S1270 (96.5 cM) and D18S70 (126.0 cM) in detail
with nine additional markers, because the initial peak
was broad and the distal end of the peak remained
elevated. Two-point analysis supported linkage for
D18S541 (LOD¼ 3.37) and D18S844 (LOD¼ 2.06).
With additional markers, the peak came down to the
right of D18S844. The two markers to the distal end of
D18S844, namely D18S1122 (122.8 cM) and D18S70
(126.0 cM), had LOD scores of 0.76 and 0.18,
respectively, suggesting a boundary of the peak. In
the multipoint analysis, the support for linkage was
strongest at D18S1106 (NPL¼ 3.65, P¼ 0.000177;
111.7 cM), which is located less than 1 cM away
from D18S541; further, the peak was much narrower
than in the first-stage scan (Figure 1). As the peak was
quite narrow, we conducted an additional analysis to
assess the likelihood of genotyping errors leading to a
sharp false-positive peak, by repeating the multipoint
linkage analysis of the peak region excluding one
marker at a time. If the peak were due to genotyping
errors, it is expected that the linkage at the peak
region would diminish; however, the magnitude of
the NPL score change for each marker was minimal
(data not shown).
Using the same set of 104 families, we then
conducted a family-based association analysis using
Sib-TDT. Multiple markers on 18q met minimal
criteria for statistically significant (Po0.05) allelic
association as shown in Table 3, namely D18S465,
D18S1092, D18S1106, D18S541, D18S1358, D18S870,
and D18S58. For D18S541 and D18S870, two alleles
were associated with AD (Po0.05 uncorrected for
multiple testing). Joint linkage and association analy-
sis using PSEUDOMARKER indicated that, for
D18S541, linkage in the presence of linkage disequi-
librium did not differ significantly from the linkage
model alone (P¼ 4.4105 vs 3.1105).
Lastly, we conducted a conditional linkage analysis
based on the APOE genotype (Figure 1). This analysis
Table 2 Summary table for the two-point linkage analysisa
results
Marker information All families Late onset
families




1 D1S551 113.7 ASP 1.00 ASP 1.12
2 D2S1777 99.4 LOD 1.49 LOD 1.33
ASP 1.51 ASP 1.32
D2S1326 149.9 b ASP 1.15
D2S1353 164.5 LOD 1.52 LOD 1.59
D2S2944 210.4 ASP 1.31 ASP 1.31
3 D3S2418 215.8 LOD 1.07 b
4 D4S2366 12.9 LOD 1.59 LOD 1.31
ASP 1.10 ASP 1.03
D4S2382 57.0 LOD 1.25 LOD 1.26
D4S3335 195.1 LOD 1.10 LOD 1.25
5 D5S2488 0.0 LOD 1.14 LOD 1.12
ASP 1.57 ASP 1.76
6 GAAT3A06 36.4 LOD 1.65 LOD 1.31
ASP 1.47 ASP 1.11
D6S1280 73.1 LOD 1.58 LOD 1.58
8 D8S1136 82.3 b LOD 1.08
10 D10S1230 142.8 LOD 1.28 LOD 1.15
ASP 1.19
12 D12S1042 48.7 LOD 1.42 LOD 1.34
ASP 1.30 ASP 1.27
14 D14S587 55.8 LOD 1.73 LOD 1.62
ASP 2.00 ASP 1.69
D14S592 66.8 LOD 1.52 LOD 1.28
ASP 1.32 ASP 1.16
18 D18S541 106.8 LOD 3.14 LOD 3.62
ASP 3.26 ASP 3.40
D18S844 116.4 LOD 2.44 LOD 2.98
ASP 1.51 ASP 2.01
aThe results from the affecteds-only dominant model under
the assumption of genetic homogeneity (LOD) and affected
sibpair (ASP) model are shown.
bThe cells with lod scores less than one for both models are
left empty.
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revealed that the peak on the 18q largely derived from
individuals who were APOE4-positive, and the peak
essentially disappeared when we considered APOE4-
negatives.
10q With 12 additional markers near D10S1230, the
location narrowed somewhat. The two markers that
gave the strongest signals from the two-point analysis
were D10S190 (LOD¼1.81) and D10S1230
(LOD¼ 1.34). The multipoint analysis revealed the
strongest peak at 138 cM near D10S190 (NPL¼ 2.02;
P¼0.0157) (Figure 2). With saturation of 10q, our
peak shifted slightly proximal compared with our
initial mapping, and yet the candidate region remains
broad, spanning over 50 cM.
Our subsequent family-based association analysis
further supported the findings from the linkage
analysis. Although multiple markers in this region
supported allelic association as shown in Table 3, the
strongest allelic association was observed with
Figure 1 The multipoint nonparametric analysis for 18q from the second-stage fine mapping using all families. The heavy
solid line represents the linkage analysis using all families; the light solid line the Apolipoprotein E e4-positive conditional
linkage analysis; and the dotted line the Apolipoprotein E e4-negative conditional linkage analysis. Map distances are based
on the Marshfield genetic map. (Marshfield Medical Research Foundation, Center for Medical Genetics, http://
research.marshfieldclinic.org/genetics/).
Table 3 Fine-mapping family-based association analysis of 18q and 10q
Marker Allele cM Z0 P-valuea Marker Allele cM Z0 P-valuea
18q 10q
D18S465 7 99.2 1.731 0.0417 D10S1432 6 93.9 1.683 0.04619
D18S1092 1 107.0 1.688 0.0457 D10S580 5 96.7 2.187 0.01437
D18S488 3 110.9 1.643 0.0502 D10S2327 6 100.9 1.702 0.04438
D18S1106 11 111.7 1.693 0.0452 rs13595 1 113.9 1.828 0.03378
D18S541 22 112.3 1.804 0.0356 rs4925 2 130.2 1.692 0.04532
17 1.801 0.0359
D10S610
7 133.1 1.718 0.04290
D181358 1 112.4 2.125 0.0168 D10S1230 5 142.8 1.704 0.04419
D18S870 1 113.8 2.407 0.0080 7 3.228 0.00062
D18S58 7 115.6 2.047 0.0203 D10S1213 4 148.2 1.865 0.03109
D18S1122 8 122.8 2.113 0.0173 D10S1222 7 156.3 2.042 0.02058
D10S1223 7 156.3 2.744 0.00304
aOnly the alleles with a nominal P-value o0.05 are listed. P-values are not corrected for multiple testing.
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D10S1230 (Z¼3.23, P¼ 0.000623). This is the most
likely cause of the linkage from our sample. In
addition, D10S610 and rs4925 at around 130 cM also
showed modest allelic association.
We examined 10q using the two-point joint linkage
and association approach. In this set of analyses,
D10S190 (at 138 cM; LOD¼ 1.95 under the autosomal
recessive model) and D10S1230 (at 143 cM;
LOD¼1.28 under the autosomal dominant model)
showed only modest linkage as well as linkage in the
presence of linkage disequilibrium. The autosomal
recessive model showed stronger support than the
autosomal dominant model. In the smaller peak at
around 115 cM, D10S583 showed a significant result
for linkage disequilibrium given linkage under the
autosomal recessive model (P¼0.003869), as well as
for a joint linkage and linkage disequilibrium test
under the autosomal recessive model (P¼ 0.004188).
No other markers showed support for this region.
As our peak for the AD phenotype centered on
D10S190 and Li et al35 reported allelic association
between glutathione S-transferase omega-1 (GSTO1)
and GSTO2 with age at onset of AD and Parkinson’s
disease (PD), we examined allelic association for
Figure 2 The multipoint nonparametric analysis for 10q from the second-stage fine mapping using all families. The
locations and markers of reported suggestive linkage findings by other groups on 10q are shown below. To estimate
confidence intervals, we subtracted one from the highest reported LOD Score. The number next to each bar or dot indicates
the reference (1. Bertram et al., 2000; 2. Ertekin-Taner et al., 2002; 3. Myer et al., 2000; 4. Kehoe et al., 1999; 5. Blacker et al.,
2003; 6. Myer et al., 2002; 7. Farrer et al., 2003; 8. Li et al., 2003; 9. Ertekin-Taner et al., 2003). Map distances are based on
the Marshfield genetics map (Marshfield Medical Research Foundation, Center for Medical Genetics, http://research.
marshfieldclinic.org/genetics/).
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seven markers (D10S583, D10S1671, D10S670,
rs4925, D10S1429, D10S610, D10S187) near GSTO1
using the age at onset as the phenotype. We did not
find a significant association with rs4925 (P¼0.4);
further, the age at onset was slightly lower for the
individuals with more common allele compared with
those with rare allele (73.4 vs 75.6 for common vs rare
allele, respectively). However, we did observe a weak
association with D10S610 (F¼ 5.51, P¼ 0.02), which
is approximately 3 cM away from the rs4925 SNP. The
strongest association with AD was with marker
D10S1230 (P¼0.0006), approximately 12 cM distal.
For both 18q22 and 10q, we reanalyzed the two-
point and multipoint linkage analyses previously
described using the allele frequencies estimated from
one randomly selected individual from each family to
reduce the influence that large extended pedigrees
may have on allele frequency estimation. However,
the allele frequencies were comparable and the LOD
and NPL scores remained unchanged.
Discussion
In this unique group of Caribbean Hispanics with
familial AD, we observed a modest peak at chromo-
some 10q near 138 cM, which spans approximately
15 cM and a weaker peak at 115 cM. The major peak
on 10q was more distal than those reported by some
groups.6–8 A new peak was identified at 18q22, and
with additional fine mapping the region surrounding
the peak narrowed considerably, and there existed
evidence of an epistatic effect with APOE e4.
Overall, 17 markers had an LOD score of greater
than or equal to one in the first stage of the genome
scan reported here. Other genome-wide searches3,9,37–
39 have reported many of these loci, for example, 1q,
10q, 12p, 14q, while some are new. For example,
Kehoe et al3 and Blacker et al38 reported a modest
peak on 1q23 (178 cM). We do observe weak linkage
in the region, but observed a stronger finding in a
more proximal location at B114 cM. For 14q, we
observed a peak on D14S587 (55 cM) as Blacker et al38
did in ‘early/mixed’ families; however, our samples,
based predominantly on late-onset AD individuals,
showed linkage to the same region. For 10q, 12p, and
18q, we chose to fine map these candidate regions
because we observed strong evidence for linkage, and
others reported strong linkage.
The observed variability in linkage findings is not
surprising given the genetic complexity of AD.
Specifically, there are likely to be multiple suscept-
ibility genes, incomplete penetrance, and putative
environmental risk factors. In addition, these studies
use different genetic models, multiple testing of
markers, and different study samples from different
ethnic backgrounds. The primary goal of our study
was to identify candidate regions that may contain
AD susceptibility genes. According to the criteria
suggested by Lander and Kruglyak,40 loci on chromo-
somes 10q26, 12p12, and 18q21 linked to AD would
fulfill the criteria for suggestive of linkage. Some of
the loci we observed from our genome-wide search
will likely be false-positives. Thus, the findings here,
as with any other genome scan, will need indepen-
dent confirmation.
At least four loci have been linked to AD on
chromosomes 9p, 10q, 12p, and 20p. However,
though several putative loci have been linked to
familial AD, only a few reports of allelic variation
have been reported, but these reports need to be
confirmed in independent samples. Pericak-Vance et
al9 identified a locus on chromosome 12p conferring
susceptibility to AD. Subsequent work by her group,
ourselves, and others has suggested that there may be
two separate loci on chromosome 12 depending on
the presence of APOE-e4 and clinical heterogeneity
related to the presence of Lewy bodies.5,10,16,36,38,39,41
In the initial scan, Kehoe et al3 observed a peak at 12p
only for the APOE-e4 negative families, not for the
APOE-e4-positive families. However, when Blacker et
al38 followed up the earlier genome scan using a larger
sample, the support for linkage on 12p weakened.
Previously, we reported our fine-mapping results that
showed two peaks near D12S1623 (16 cM) and
D12S1042 (49 cM).16 When we restricted the analysis
to late-onset AD families, both markers showed strong
linkage. When we conducted the analysis stratified by
the APOE status, the linkage for D12S1623 was
observed only in the APOE e4-negative families.
Two candidate genes in the region, alpha-2-macro-
globulin (A2M [MIM 103950]) and the low-density
lipoprotein receptor-related protein (LRP1 [MIM
107770]), have been the target of investigations, but
without consistent results.16,36,42–45 Saunders et al,46
using the larger NIMH samples, identified several
haplotypes that showed an association with AD,
suggesting that there may be a gene—either A2M or
one nearby—that may confer a modest effect toward
AD.
Linkage findings on 10q also provide an illustration
of the difficulties in replicating linkage and in
estimating the location of gene underlying complex
disorders.47,48 Six studies based on three different but
correlated phenotypes (familial AD;3,6,8,38 variation in
plasma amyloid b levels;7 and age at onset of AD34)
showed evidence of linkage to 10q. The peaks in these
studies cover a wide chromosomal region from 81 to
135 cM; however, it is not possible to determine
whether these represent one or multiple loci.48 Three
studies3,6,7 found the strongest support for linkage at
B81 cM (D10S1227–D10S1211), while Bertram et al8
observed a peak between 115 and 127 cM, and later
Blacker et al38 reported a peak at 135 cM (D10S1237)
in a two-point analysis (y¼0.25). Using age at onset
as the phenotype, Li et al34 reported a peak at 135 cM
using the same marker (D10S1237) as Blacker et al,
and subsequently reported an association with
GSTO1. As we observed a peak nearby at 138 cM
with the AD phenotype, we examined allelic associa-
tion using both AD and age at onset phenotypes. For
the age at onset phenotype, we did not find an
association with rs4925 (P¼ 0.4), but we did observe a
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weak association with D10S610 (F¼5.51, P¼ 0.02),
which is approximately 3 cM away from the rs4925
SNP. For the AD phenotype, however, we observed
weak allelic associations for rs4925 (Z¼1.692;
P¼ 0.045323) as well as D10S610 (Z¼1.718;
P¼ 0.042898). Although we did observe a weak
association in the region, our finding is somewhat
different from that of Li et al. The mean age at onset
observed in our samples was comparable to that
reported by Li et al. Yet, our association with rs4925 is
weak for the AD phenotype and not significant for the
age at onset phenotype. Further, while Li et al found
the less common allele to be associated with later age
at onset, we did not observe any difference in the
mean age at onset between the two alleles. Further
studies are needed to understand the allelic associa-
tion since our finding is based on a relatively small
sample of Caribbean Hispanics, while that of Li et al’s
findings is based on a larger set of US Caucasians.
Thus, at this point, it is not possible to conclude
whether GSTO1 or some other gene is responsible for
our linkage and association finding in this region.
In contrast, Bertram et al8 reported significant peaks
at 115 cM (D10S583) and 127 cM (D10S1671), and
observed allelic association at D10S583, located near
the gene insulin degrading enzyme (IDE [MIM
146680]). Ait-Ghezala et al49 supported this finding
in a follow-up case–control study. However, Abraham
et al50 could not confirm the association with
D10S583 or with SNPs flanking IDE. In a subsequent
genome scan, Blacker et al38 reported two modest and
broad peaks on 10q: one more proximal (80–100 cM)
than the previously reported peaks (115 and 127 cM)
and another at 135 cM. In our data, we did observe a
modest peak at 138 cM. Given that multiple data sets
using multiple correlated phenotypes show modest
support for linkage on 10q covering a wide region, a
susceptibility gene, if present, may only confer a weak
effect. Alternatively, there may be more than one gene
involved and they may interact. In our conditional
analysis of APOE 4, we did find a slightly stronger
evidence of linkage at the D10S190, but it was not
statistically significant. Lastly, Ertekin-Taner et al7
reported linkage to 10q (B80 cM) for plasma amyloid
b protein levels as an intermediate risk factor
phenotype for AD, then they subsequently reported
the QTL locus to be the a-T catenin gene.51 In our data
set, we did not observe any signal in this region when
we used the AD phenotype.
An additional locus on chromosome 9p22 has been
linked to AD from different samples: two studies in
the US Caucasians;4,38 and in inbred Israeli Arabs.39
On chromosome 20p, AD8 [MIM607116]), a locus that
includes the gene encoding cystatin-C (CST3 [MIM
604312]), was linked to very late-onset AD,37 and
appeared to interact with the amyloid precursor
protein. In contrast, we did not observe any support
for linkage in these two regions to the AD phenotype.
It is important to note that, with the exception of
the studies by three groups (Ertekin-Taner et al,7
Farrer et al,39 and the current study), all other studies
include some subsets of the NIMH samples; thus,
overlapping linkage peaks from different studies need
to be interpreted with caution.
Our most robust linkage finding on 18q was
previously reported by Pericak-Vance et al4 to have
an LOD score of 1.1. With additional markers, the
linkage peak sharpened, and the peak centers around
D18S541, since both the joint linkage and association
analysis and family-based association analysis
strongly support D18S541. As with any genome scan,
it is difficult to exclude the possibility of a false-
positive finding. However, the addition of more
markers narrowed the chromosomal region consider-
ably, and the NPL score attained greater statistical
significance. Further, the distal peak tapered off,
arguing against the possibility of a spurious finding
that occurs at the distal ends of the chromosome.
Subsequent re-analyses of the region—first by se-
quentially excluding one marker at a time and second
by using the allele frequencies based on a single
randomly selected individual per family, rather than
using all family members—did not change the LOD or
NPL scores, suggesting that the observed linkage is
less likely to be due to either genotyping errors or due
to inaccurate allele frequency estimates.
This region on 18q contains approximately
4 000 000 base pairs including several candidate genes
for which mRNA expression in brain has been
observed. These include NETO1, a neuropilin (NRP)
and tolloid (TLL)-like protein, and the predicted
RefSeq genes for HSPC154 and MGC39671. There
are also approximately 50 genes predicted using the
Genscan Gene prediction track of the UCSC Genome
Browser in the region.
We did not observe significant linkage to APOE in
either the two-point or multipoint analyses. Similarly,
we did not observe an association between APOE-e4
and sporadic Alzheimer disease in the randomly
selected Caribbean Hispanics, suggesting that APOE
confers a weak effect in this population.12,13 Among
familial AD, however, we reported14 the APOE-e4
allele to be strongly associated (Z¼ 4.26,
P¼ 1.01105). In the current study, the joint linkage
and association analysis of APOE yielded a P-value of
0.00802 for linkage disequilibrium under the domi-
nant model, a P-value of 0.04863 for linkage, and a P-
value of 0.00408 for a joint test of linkage and linkage
disequilibrium. As expected, the linkage to APOE was
weak. This illustrates the difficulties in identifying
relatively common alleles, with weak to modest
effects when studying late-onset disorders.
In sum, this was the first genome scan focused on
familial AD in Caribbean Hispanics. We observed
suggestive evidence for linkage to chromosome 18q
and continue to support evidence for linkage to 10q.
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